Enjoy complimentary customisation on priority with our Enterprise License!
The infectious disease diagnostics market size is forecast to increase by USD 8.90 billion at a CAGR of 4.5% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of infectious diseases worldwide. Additionally, the market is witnessing an increase in mergers and acquisitions as major players seek to expand their product portfolios and geographical reach. However, the availability of counterfeit drugs in developing economies poses a significant challenge to market growth. To mitigate this issue, regulatory bodies are implementing stricter regulations and collaborating with industry players to ensure the authenticity and quality of diagnostic products. Overall, the market is expected to grow steadily due to these factors, with a focus on innovation and collaboration to address the evolving needs of the healthcare industry.
The market encompasses a range of medical testing technologies used to identify causative organisms of various infectious diseases, including tuberculosis, HIV or AIDS, hepatitis, sexually transmitted infections, and respiratory infections. The market's growth is driven by the increasing disease prevalence and the need for prompt diagnosis in urgent care centers, emergency rooms, ambulances, and clinical laboratories. Skilled technicians and physicians utilize various laboratory tests, such as urine, mucus, and body fluids samples, to diagnose these diseases using advanced instruments. Infection control and personal health are crucial considerations in the diagnostics process, emphasizing the importance of hygiene and rapid results.
Furthermore, medical tourism also plays a role in the market's growth, as individuals travel to access specialized diagnostic services not available in their home countries. Overall, the infectious diseases diagnostics market is essential in ensuring effective infection control, improving patient outcomes, and saving lives.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The hospitals segment is estimated to witness significant growth during the forecast period. The global market is experiencing substantial growth due to the importance of prompt diagnosis in controlling the spread of infectious diseases. Infectious diseases, including RNA viruses like Hepatitis C, bacteria, viruses, fungi, and parasites, pose a significant threat to personal health and can lead to respiratory diseases, pneumonia, and other health complications. Poor water sanitation and inadequate hygiene facilities in hospitals and other healthcare settings further increase the risk of infections. Skilled technicians and physicians rely on various diagnostic methods, such as chest X-rays, CT scans, physical exams, and laboratory tests, to identify the causative organism in samples taken from patients.
Furthermore, these samples can include respiratory secretions, blood, urine, mucus, and other body fluids. Instruments used for infectious disease diagnostics include PCR testing equipment and other advanced laboratory tools. The hospital segment is expected to dominate the market due to the increasing number of patients suffering from various infectious diseases, such as tuberculosis, meningitis, and COVID-19. According to recent data, there are approximately 50,733 hospitals worldwide, and this number is continually increasing. Large-, medium-, and small-sized hospitals procure medical products, including infectious disease diagnostic instruments, in bulk from suppliers and group purchasing organizations, driving the market growth. Government and private organizations play a crucial role in the market by investing in research and development of new diagnostic technologies and implementing infection control measures. Infections caused by pathogens result in numerous deaths annually, with geriatric populations being particularly vulnerable to pneumococcal pneumonia and other respiratory diseases. Therefore, the global market is poised for significant growth during the forecast period.
Get a glance at the market share of various segments Request Free Sample
The hospitals segment was valued at USD 23.83 billion in 2018 and showed a gradual increase during the forecast period.
Asia is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market encompasses various types of medical testing for the detection of pathogens causing diseases such as tuberculosis, HIV or AIDS, hepatitis, sexually transmitted infections (STIs), respiratory infections, and hospital-acquired infections. The prevalence of these diseases necessitates advanced diagnostic techniques, including Next Generation Sequencing, for pathogen detection in clinical laboratories. Medical tourism and procurement of diagnostic kits, consumables, software, and services from various suppliers require stringent measures for sample collection, storage, and transportation to ensure cross contamination is minimized. Diseases such as HIV, Chlamydia trachomatis, Neisseria gonorrhea, HPV, Influenza, Syphilis, and mosquito-borne diseases, among others, necessitate rapid and accurate laboratory testing.
Furthermore, point-of-care (PoC) testing and urgent care centers, emergency rooms, and ambulances require rapid results with high sensitivity and specificity to ensure timely treatment. False negative and false positive results can lead to misdiagnosis and ineffective treatment, making it crucial for laboratories to maintain stringent quality control measures. Laboratory spaces and technicians must adhere to regulatory guidelines to ensure accurate and reliable test results. With the increasing prevalence of infectious diseases, the demand for advanced diagnostic tools and techniques is expected to grow, driving the growth of the market.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of infectious diseases is the key driver of the market. Infectious diseases caused by bacteria, viruses, fungi, and parasites continue to pose a significant health threat worldwide. The rise in infectious disease outbreaks can be attributed to various factors, including poor water sanitation, inadequate hygiene facilities, and changing lifestyles that weaken immunity. The prevalence of other diseases, such as pneumococcal pneumonia, hepatitis C, and respiratory diseases, also continues to be a concern. In hospitals, healthcare professionals rely on prompt diagnosis to ensure effective infection control. Technologies like chest X-rays, CT scans, physical exams, and laboratory tests, including PCR testing, play a crucial role in identifying the causative organism from respiratory secretions, blood, urine, mucus, and other body fluids.
Furthermore, skilled technicians and physicians utilize advanced instruments to analyze these samples. Private and government organizations invest in research and development to improve diagnostics and reduce infections and deaths. The geriatric population is particularly vulnerable to infectious diseases, making the need for accurate and timely diagnosis even more pressing.
An increase in mergers and acquisitions is the upcoming trend in the market. The global market is experiencing a rise in mergers and acquisitions (M&A) among organizations, driving market growth in the rapidly expanding markets of India, Brazil, China, and South Africa. This trend is a strategic response to maintain competitive positions and tap into new opportunities in the infectious disease diagnostics industry. M&A activities aim to expand businesses by broadening product portfolios and enhancing market presence. Infectious diseases pose a significant threat to personal health and public health, particularly in settings with poor water sanitation and inadequate hygiene facilities. Hospitals, in particular, are at risk due to the high volume of patients and the presence of causative organisms such as bacteria, viruses, fungi, and parasites.
Furthermore, chest X-rays, CT scans, physical exams, and laboratory tests, including PCR testing, are essential tools for prompt diagnosis and infection control. Respiratory diseases, such as pneumonia, caused by RNA viruses like Hepatitis C and bacteria, account for a significant number of infections and deaths in hospitals, especially among the geriatric population. Rapsketit, Legionella, and Mycobacterium tuberculosis are other common pathogens that require accurate and timely diagnosis. Skilled technicians and physicians analyze respiratory secretions, blood, urine, mucus, and other body fluids using advanced instruments to identify the causative organism. Private and government organizations invest in research and development to improve diagnostics, ensuring accurate and timely detection of infectious diseases to reduce morbidity and mortality.
The availability of counterfeit drugs in developing economics is a key challenge affecting market growth. Infectious diseases pose a significant threat to personal health and public health systems, necessitating prompt diagnosis and infection control measures. Hospitals, particularly in developing countries with poor water sanitation and inadequate hygiene facilities, are hotspots for the spread of pathogens, including bacteria, viruses, fungi, and parasites. Chest X-rays, CT scans, physical exams, and laboratory tests are essential tools for diagnosing various infectious diseases. Skilled technicians and physicians analyze samples, such as respiratory secretions, blood, urine, and mucus, using instruments like PCR testing to identify the causative organism. RNA viruses, such as Hepatitis C, and respiratory diseases like pneumococcal pneumonia, are common applications.
Furthermore, government and private organizations invest in research and development to improve diagnostics and reduce deaths in American hospitals, especially among the geriatric population. However, the availability of counterfeit drugs is a growing concern in the market. These drugs, which are prevalent in low-income and developing countries due to insufficient regulations and manufacturing control, pose a significant risk to patients by providing a false sense of security while endangering them further with their contents.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories - The company offers infectious disease diagnostics for diseases such as SARS CoV 2, and HIV 1.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is witnessing significant growth due to the increasing prevalence of diseases such as tuberculosis, HIV or AIDS, hepatitis, sexually transmitted infections (STIs), respiratory infections, and hospital acquired infections. Medical testing plays a crucial role in the early detection and treatment of these diseases. Clinical laboratories are the primary consumers of infectious disease diagnostics, with technicians handling samples for pathogen detection using various methods, including next-generation sequencing and PCR. The market is driven by disease prevalence, medical tourism, and the need for rapid results in urgent care centres, emergency rooms, and ambulances. However, challenges such as cross contamination, false negative and positive results, and the need for specialized laboratory spaces, procurement, storage, and transportation of samples, pose significant hurdles.
Moreover, the market is segmented into kits, consumables, software and services, and instruments. HIV, HPV, Chlamydia trachomatis, Neisseria gonorrhea, syphilis, influenza, and mosquito borne diseases are some of the major infectious diseases under focus. The market is expected to grow at a steady pace due to the increasing demand for accurate and rapid diagnostic tests for infectious diseases. Infectious disease diagnostics are used to detect a wide range of diseases, including tuberculosis, HIV or AIDS, hepatitis, STIs, respiratory infections, hospital acquired infections, and mosquito borne diseases. Medical testing plays a crucial role in the early detection and treatment of these diseases, which is essential for improving patient outcomes and reducing the spread of infections.
Furthermore, the increasing prevalence of infectious diseases, medical tourism, and the need for rapid results in urgent care centres, emergency rooms, and ambulances are driving the growth of the market. However, challenges such as cross contamination, false negative and positive results, and the need for specialized laboratory spaces, procurement, storage, and transportation of samples, pose significant hurdles. The market is segmented into kits, consumables, software and services, and instruments. HIV, HPV, Chlamydia trachomatis, Neisseria gonorrhea, syphilis, influenza, and mosquito borne diseases are some of the major infectious diseases under focus. The market is expected to grow at a steady pace due to the increasing demand for accurate and rapid diagnostic tests for infectious diseases.
Furthermore, the use of next-generation sequencing and point-of-care (POC) testing technologies is gaining popularity in the market due to their ability to provide rapid and accurate results. These technologies are particularly useful in the detection of HIV, HPV, and other sexually transmitted infections, as well as in the diagnosis of hospital acquired infections and influenza. However, the use of these advanced technologies comes with challenges such as high cost, complex workflows, and the need for specialized expertise and infrastructure. Cross contamination is another major challenge in the market, as even the slightest contamination can lead to false positive results and compromise the accuracy of the test.
Market Scope |
|
Report Coverage |
Details |
Page number |
140 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market growth 2024-2028 |
USD 8.90 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.23 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Asia at 43% |
Key countries |
US, Germany, China, UK, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Danaher Corp., DiaSorin Spa, F. Hoffmann La Roche Ltd., Genetic Signatures Ltd., Grifols SA, Hologic Inc., Meridian Bioscience Inc., Meril Life Sciences Pvt. Ltd., OraSure Technologies Inc., Perkin Elmer Inc., QIAGEN NV, Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Trinity Biotech Plc, and Vela Diagnostics |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.